Evidence map›Paper›PMID 35435727›Full record

ArticleInfection and immunity2022

Lipidation of

Ravinder Kaur, Michael Pichichero

Open access · greenAbstract read
In one paragraph

Article in Infection and immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ravinder KaurCenter for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA.ORCID 0000-0001-6539-5339
Michael PichicheroCenter for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA.
Rochester General Hospital · US

Funding

Enhanced immunogenicity and protection study of lipid modified protein vaccine candidates of Nontypeable Haemophilus influenzaeR21AI153936 · NIAID · ROCHESTER GENERAL HOSPITAL (NY) · PI KAUR, RAVINDER · 2020 to 2021
$440k
HHS | NIH | National Institute on Deafness and Other Communication Disorders (NIDCD) R21 AI153936-01NIAID NIH HHS R21 AI153936
6 · The paper itself

Abstract

Nontypeable Haemophilus influenzae (NTHi) causes respiratory infections that lead to high morbidity and mortality worldwide, encouraging development of effective vaccines. To achieve a protective impact on nasopharyngeal (NP) colonization by NTHi, enhanced immunogenicity beyond that achievable with recombinant-protein antigens is likely to be necessary. Adding a lipid moiety to a recombinant protein would enhance immunogenicity through Toll-like receptor 2 signaling of antigen-presenting cells and Th17 cell response in the nasal-associated lymphoid tissue (NALT). We investigated effects of lipidation (L) of recombinant proteins P6 and OMP26 compared to nonlipidated (NL) P6 and OMP26 and as fusion constructs (L-OMP26ϕNL-P6 and L-P6ϕNL-OMP26) in a mouse model. After intraperitoneal or intranasal vaccination, antibody responses were compared and protection from NP colonization and middle ear infection were assessed. L-P6 and L-OMP26 induced approximately 10- to 100-fold-higher IgG antibody levels than NL-P6 and NL-OMP26. Fusion constructs significantly increased IgG antibody to both target proteins, even though only one of the proteins was lipidated. NP colonization and middle ear bullae NTHi density was 1 to 4 logs lower following vaccination with L-P6 and L-OMP26 than with NL-P6 and NL-OMP26. Fusion constructs also resulted in a 1- to 3-log-lower NTHi density following vaccination. NALT cells from mice vaccinated with lipidated protein constructs had higher levels of interleukin-17 (IL-17), IL-22, and CD4

Indexed as

Haemophilus InfectionsHaemophilus VaccinesOtitis MediaAnimalsAntibodies, BacterialAntigens, BacterialBacterial Outer Membrane ProteinsHaemophilus influenzaeHumansImmunoglobulin GMiceAntibodies, BacterialAntigens, BacterialBacterial Outer Membrane ProteinsHaemophilus VaccinesImmunoglobulin Gacute otitis mediaantibodiesHaemophilus influenzaelipidated recombinant proteinsnasopharyngeal colonizationOMP26P6Th17 immunityTLR2

Identifiers

PMID35435727
PMCPMC9119059
OpenAlexW4224029630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.